Start with what the trials measured
If you are considering sermorelin, the most useful thing you can know is what the human studies actually tracked — because that is the ceiling of what anyone can honestly promise. (If you haven’t read it yet, our explainer covers what sermorelin is and its regulatory status.)
| Trial | Who | How long | What changed | What didn’t |
|---|---|---|---|---|
| GHRH 1-29 nightly, 2 mg (Vittone 1997) | 11 healthy men, 64–76 | 6 weeks | Two strength measures and one endurance measure | Weight, BMI, waist-to-hip ratio, DEXA body composition, IGF-1 |
| GHRH daily (Vitiello 2006) | 89 healthy older adults, mean age 68 | 6 months | Performance IQ, attention, executive function | — (cognition study) |
| Tesamorelin, a longer-acting GHRH analog, 1 mg before bedtime (Baker 2012) | 152 adults, with and without mild cognitive impairment | 20 weeks | Cognition, including executive function | — (cognition study) |
Three things stand out. The trials are small. The longest is six months. And none of them showed fat loss.
A realistic timeline
Weeks 1–2: the injection becomes routine. Sermorelin is a small subcutaneous injection, typically at bedtime — the trials above dosed before bed because growth hormone is released mostly in overnight pulses. The practical learning curve is the injection itself: site rotation, storage, timing. Nothing in the literature supports expecting a felt change this early.
Weeks 3–6: the earliest measured window. The six-week trial is the shortest we have. It found improvement on specific strength tests (upright row, shoulder press, abdominal endurance) while finding no change in weight or body composition and, notably, no rise in IGF-1 — the blood marker usually used as a proxy for growth-hormone activity (Vittone 1997). If your provider repeats labs at this point, an unchanged IGF-1 is not evidence that nothing is happening; it is what the trial saw too.
Months 3–6: where the cognition signals appeared. Both cognition trials ran five to six months before reporting benefit (Vitiello 2006; Baker 2012). This is also the horizon at which a provider will usually ask the real question: is this doing anything for you that justifies continuing?
Beyond 6 months: no data. There are no long-term outcome trials of sermorelin in healthy adults. Reviews of GHRH and growth-hormone secretagogues in normal aging concluded the evidence “do[es] not yet support the routine use of GHRH or GHS in normal aging” (Merriam 2003), and a 2025 review of growth hormone and aging calls long-term safety for healthy aging “uncertain” (Fernández-Garza 2025). Continuing past six months is a judgment call made with your provider, not a default.
What “working” should look like
Because the trials measured strength and cognition, those are the honest yardsticks:
- Measurable strength on the same lifts you were doing before.
- Subjective attention and executive function — the trials used formal testing; at home, the honest version is “am I getting more done, more easily?”
- Sleep quality is widely claimed but the evidence is mixed: GHRH improved non-REM sleep after sleep deprivation in one study (Schüssler 2006) and impaired sleep in healthy young women in another (Mathias 2007). Track it, but don’t expect it.
What working should not look like: rapid fat loss, visible muscle gain in weeks, or “feeling 25 again.” Those claims come from marketing, not from the three trials above.
What to tell your provider along the way
- Joint aches, swelling in the hands or feet, or tingling fingers. These are the known effects of raising growth-hormone activity in general (fluid retention, arthralgia, carpal tunnel symptoms) catalogued for growth hormone itself (Fernández-Garza 2025). The six-week sermorelin trial reported no significant adverse effects, but it was six weeks and eleven men.
- Blood-sugar changes. Growth hormone opposes insulin; your provider may track fasting glucose or A1c.
- Injection-site redness or lumps that don’t settle within a day or two.
- Any new diagnosis, especially a cancer evaluation — a reason to stop and reassess.
How it ends
Sermorelin at BioPeakRx is a monthly, cancel-anytime subscription with 30 days’ notice. The right way to stop is the same as the right way to start: a conversation with your provider about whether the measured benefits are worth it. There is no taper in the trials, and no rebound is described.
Compounded medications are not FDA-approved. This article is education, not medical advice, and does not establish a provider–patient relationship. Pricing and the therapy page are at /treatments/sermorelin/.
Sources: Vittone J et al., Metabolism 1997 (PMID 9005976) · Vitiello MV et al., Neurobiol Aging 2006 (PMID 16399214) · Baker LD et al., Arch Neurol 2012 (PMID 22869065) · Merriam GR et al., Endocrine 2003 (PMID 14610297) · Schüssler P et al., 2006 (PMID 16912060) · Mathias S et al., 2007 (PMID 17850984) · Fernández-Garza LE et al., Front Aging 2025 (PMC12009952)